Related references
Note: Only part of the references are listed.Evidence and implementation gaps in management of sentinel node-positive melanoma in the United States
Kristy K. Broman et al.
SURGERY (2022)
Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy trial II (MSLT-2)
Kristy Kummerow Broman et al.
CANCER (2021)
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
C. N. Owen et al.
ANNALS OF ONCOLOGY (2020)
Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy
Norma E. Farrow et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management
Daan Jan Willem Rauwerdink et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Management of the positive sentinel lymph node in the post-MSLT-II era
Brooke C. Bredbeck et al.
JOURNAL OF SURGICAL ONCOLOGY (2020)
Immunotherapy in resected stage III melanoma: An analysis of the National Cancer Database
Justin T. Moyers et al.
CANCER RESEARCH (2020)
Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma
Joanna Mangana et al.
MELANOMA RESEARCH (2019)
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Alexander M. M. Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2019)
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
Ulrike Leiter et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide and Interleukin-2 Adjuvant Therapy in Resected High-Risk Primary and Regionally Metastatic Melanoma
Amitoj Gill et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2019)
Updates in adjuvant systemic therapy for melanoma
Minyoung Kwak et al.
JOURNAL OF SURGICAL ONCOLOGY (2019)
Surveillance imaging for metastasis in high-risk melanoma: importance in individualized patient care and survivorship
Morganna Freeman et al.
MELANOMA MANAGEMENT (2019)
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W. Joseph et al.
CLINICAL CANCER RESEARCH (2018)
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio et al.
LANCET ONCOLOGY (2018)
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
Brigitte Dreno et al.
LANCET ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
Michael Lattanzi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma
Kok Haw Jonathan Lim et al.
ESMO OPEN (2018)
PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study
Max F. Madu et al.
MELANOMA RESEARCH (2017)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
M. B. Faries et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
Parisa Momtaz et al.
ONCOTARGET (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients
Tristen S. Park et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study
Sebastian Podlipnik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter et al.
LANCET ONCOLOGY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
Michal Lotem et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
Mizuki Nishinol et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Hazard-Rate Analysis and Patterns of Recurrence in Early Stage Melanoma: Moving towards a Rationally Designed Surveillance Strategy
April K. S. Salama et al.
PLOS ONE (2013)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
Stephen B. Edge et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines
Emanuela Romano et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?
Ulrike Leiter et al.
MELANOMA RESEARCH (2010)
A basic introduction to fixed-effect and random-effects models for meta-analysis
Michael Borenstein et al.
RESEARCH SYNTHESIS METHODS (2010)
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
AMM Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2004)
Medical management of melanoma
CK Brown et al.
SURGICAL CLINICS OF NORTH AMERICA (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Combination chemotherapy with or without s.c. IL-2 and IFN-α:: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)
J Atzpodien et al.
BRITISH JOURNAL OF CANCER (2002)
Share Paper
